EUVIMEDEUVIMED entdecken
Crossref

Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps

J Maza-Solano, L Garcia Mochon, J Martin-Martin, P W Hellings, S Sanchez-Gomez

Rhinology Journal · 01.05.2026 · 0-0

DOI: 10.4193/rhin25.529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rhinology Journal, online erschienen am 01.05.2026. Verfasst von J Maza-Solano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen del Rocio, Seville, Spain;Department of Surgery, University o…. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Endoscopy, Biological Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) imposes major health and economic burdens. Endoscopic sinus surgery (ESS) and biologic therapy are treatment options. This study compares their effectiveness and cost-efficiency from the Spanish National Health System (NHS) perspective. Methodology: An economic evaluation was conducted in severe CRSwNP, following Spanish-NHS guidelines. Data came from a tertiary-hospital with 10-year projections. Effectiveness was measured as reduction in the Sinonasal Outcome Test-22 (SNOT-22). Cost-utility analysis used quality-adjusted life years (QALYs). Micro-costing was applied for ESS, while annual drug costs were considered for biologics. Sensitivity analyses tested robustness.

Results

89 patients were included (63 ESS, 26 biologics). After 2-years, both strategies achieved similar SNOT-22 improvements (-31.8 ESS, -31.0 biologics). Costs were far lower for ESS (€5,302.78) than biologics (€27,198.23), making biologics less efficient despite comparable benefit. The 2-year incremental cost-utility ratio (ICUR) for biologics was €1.2 million/QALY, above accepted thresholds. At 10-years, biologics yielded 2.75 QALYs at an incremental cost of €108,917.62 (ICUR €39,592/QALY). Sensitivity ana-lyses showed that biologics generally remained above commonly accepted willingness-to-pay thresholds, although substantial price reductions (up to 40%) allowed ICURs to approach the upper limit of acceptability.

Conclusions

Both treatments provide meaningful improvement. ESS remained the less costly strategy and was more efficient over the short term, whereas long-term projections showed higher QALY gains with biologics at substantially greater cost. Within Spanish- NHS, biologics may approach cost-effectiveness only under favorable pricing assumptions and should be reserved for patients with contraindications or persistent disease after ESS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsEndoscopyBiological TherapySinusitisHumansChronic DiseaseCost-Benefit AnalysisQuality-Adjusted Life YearsCost-Effectiveness AnalysisFemaleSpainMaleMiddle AgedAdult

Autor:innen und Institutionen

  • Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen del Rocio, Seville, Spain;Department of Surgery, University of Seville, Seville, Spain.
  • Biomedical Research Center at Ciber for Epidemiology and Public Health (CIBERESP by its Spanish acronym), Madrid, Spain;IBS Biomedical Research Institute, Granada, Spain;Department of Applied Economics, University of Gr…
  • Department of Applied Economics, University of Granada, University Campus of Cartuja s/n, Granada, Spain.
  • Dept Otorhinolaryngology, University of Leuven, Belgium;Laboratory of Allergy and Clinical Immunology, University of Leuven, Belgium;Upper Airways Research Group, University of Ghent, Belgium.
  • Department of Surgery, University of Seville, Seville, Spain;Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain.

Zitieren

APA

Maza-Solano, J., Garcia Mochon, L., Martin-Martin, J., Hellings, P. W., & Sanchez-Gomez, S. (2026). Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin25.529

Vancouver

Maza-Solano J, Garcia Mochon L, Martin-Martin J, Hellings PW, Sanchez-Gomez S. Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps. Rhinology Journal. 2026;0(0):0-0. doi:10.4193/rhin25.529

BibTeX
@article{MazaSolano2026,
  author = {Maza-Solano, J and Garcia Mochon, L and Martin-Martin, J and Hellings, P W and Sanchez-Gomez, S},
  title = {Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps},
  journal = {Rhinology Journal},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {0--0},
  doi = {10.4193/rhin25.529}
}
Kostenlos starten →